Skip to content
Search

Latest Stories

Top Stories

Dark magic: Drug companies and the art of deception

Dark magic: Drug companies and the art of deception
Getty Images

Pearl is a clinical professor of plastic surgery at the Stanford University School of Medicine and is on the faculty of the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.

Magicians know the key to a convincing trick is misdirection.


They instruct you to follow the left hand so that you’ll ignore the right, which is subtly palming a ball or pulling an ace from the sleeve. The art of the illusion hinges on the magician’s ability to divert attention from where the real action is happening. And, therefore, every illusion conceals the truth.

Similarly, the U.S. biopharmaceutical industry has relied on subtle forms of misdirection in response to increased scrutiny from Congress, the Biden administration and health policy experts.

Here are three illusions drug companies have crafted to maintain massive profitability:

Illusion No. 1: A Death-Defying Feat

Drug research and development (R&D) has, for decades, gifted humanity with medical wonders: antibiotics, statins, cancer therapies and HIV/AIDS treatments.

In the 21st century, however, drug innovation has slowed while pharma companies have made exorbitant pricing a key business strategy. Over the past 18 years, biopharma companies have earned an average gross profit margin of 77%. Last year, the five largest pharma firms generated more than $81.9 billion in profits.

Sign up for The Fulcrum newsletter

To combat runaway drug prices, Congress passed the Inflation Reduction Act last year, allowing the U.S. government to negotiate prices for a limited number of expensive medications starting in 2026.

The pharmaceutical sector immediately filed lawsuits. In public remarks, drug spokespeople have created the illusion that any reduction in drug-industry profits will destroy R&D innovation and harm millions of patients.

The Hidden Truth

Hidden in this illusion are three facts drug companies don’t want Americans to know. Combined, these truths tell a different story about pharmaceutical research and development.

First, an overwhelming percentage of drug prices gets channeled into corporate profits and administrative costs, not R&D. In fact, a report during the height of the pandemic found that 7 in 10 major drug companies spent more on marketing and sales than R&D.

Second, research concludes that price constraints would minimally impact drug discovery. The Congressional Budget Office estimates that reducing the pharmaceutical revenues would result in just one less drug over the next decade and a total of 1% fewer medications over the next 30 years.

The third and most pernicious part of the illusion is getting people to ignore how many Americans are harmed by the unaffordability of life-essential medications. One example is insulin prices, which have tripled over the past decade. As a result, researchers from Yale found 25% of children with type 1 diabetes are given lower doses by their parents than their physicians recommend.

Nearly 1 in 4 Americans on prescription drugs now report difficulty affording their medications. That is the hidden truth. Exorbitant Rx prices hurt and kill far more Americans than the supposed loss of R&D ever would.

Illusion No. 2: The Statue Of Liberty Trick

Once Americans buy into the illusion that exorbitant drug prices are necessary to save lives, pharmaceutical companies move on to the next sleight of hand.

It goes like this: The United States, alone, must shoulder the enormous burden of drug prices.

Right now, Americans pay 2.4 to 3.4 times more for medications than in peer nations.

Much of the disparity in spending dates back to 2003 when Congress passed a law prohibiting the U.S. government from negotiating drug prices. And without any pricing regulations in place, domestic drug companies have pushed the boundaries ever higher. Over the past two years, nearly half of FDA approved medications have debuted above $150,000 with several topping $1 million per patient.

Outside of the United States, excessively high drug prices are a rarity.

Ozempic exemplifies the problem. This diabetes drug helps people lose significant weight while also avoiding heart attacks. A month’s supply of it costs $936 in the United States. In Japan, it sells for $169. It’s just $93 in the UK, $87 in Australia and $83 France.

Each of these countries has instituted drug-pricing controls and caps on drugmaker profits. If our nation adopted the same regulations, we could prescribe Ozempic to every overweight and obese American, and affordably solve the obesity epidemic. But under current retail pricing, doing so would increase drug spending $1.5 trillion per year, raising overall healthcare costs by 25%.

The Hidden Truth

The illusion here is that drug prices in other wealthy nations are non-negotiable.

But of course, that’s not accurate. American drug companies could play hardball with peer countries, refusing to sell their medications unless a more equitable pricing structure can be reached.

But why bother when you can simply stick Americans with the bill?

Illusion No. 3: What’s In Your Pocket?

When it comes to purchasing prescription drugs, there are two prices. There’s the very high retail price drug companies charge and the much-smaller amount insured patients pay when they pick up their medications (the out-of-pocket expense).

Since out-of-pockets are only small fraction of the total drug expense, drug companies would like Americans to concentrate on those dollars. But that requires people to assume the rest of the money—paid by the government or private businesses—is free.

The Hidden Truth

The reality is that workers and taxpayers wind up paying the price for expensive medications in two ways:

1. Workers earn less pay as benefit costs increase. That’s because employers treat wages and healthcare benefits as a single expense. As medical costs soar, raises disappear and salaries stagnate.

2. Taxpayers either pay more or get less. When medical costs rise, the government must either raise taxes or cut programs, including school funding and public safety.

Deception and misdirection can be sources of wonder at magic shows. But illusions in healthcare prove to be disturbing, dangerous and deadly.

Read More

Trump to the Nation: "We're Just Getting Started"

U.S. President Donald Trump speaks to a joint session of Congress at the U.S. Capitol on March 04, 2025 in Washington, DC. President Trump is speaking about the early achievements of his presidency and his upcoming legislative agenda.

(Photo by Mandel Ngan-Pool/Getty Images)

Trump to the Nation: "We're Just Getting Started"

On Tuesday, President Donald Trump addressed a joint session of Congress, emphasizing that his administration is “just getting started” in the wake of a contentious beginning to his second term. Significant themes, including substantial cuts to the federal workforce, shifts in traditional American alliances, and the impact of an escalating trade war on markets, characterized his address.

In his speech, Trump highlighted his actions over the past six weeks, claiming to have signed nearly 100 executive orders and taken over 400 executive actions to restore “common sense, safety, optimism, and wealth” across the country. He articulated that the electorate entrusted him with the leadership role and stressed that he was fulfilling that mandate.

Keep ReadingShow less
Trump’s Tariffs: a burden on workers, a boon for the wealthy

An illustration of a deconstructed dollar bill.

Getty Images, rob dobi

Trump’s Tariffs: a burden on workers, a boon for the wealthy

Earlier this year, President Trump imposed tariffs on Canada, Mexico, and China, claiming they would fix trade imbalances and protect jobs. However, instead of helping American workers, these tariffs act as hidden taxes; they drive up costs and feed inflation. While average Americans bear the brunt of higher prices and lost jobs, the wealthy are insulated from the worst effects.

Many economists assert that tariffs are stealth taxes, that is, the burden is not distributed equally—while corporations may adjust by diversifying suppliers or passing costs along, working households cannot escape higher prices on essential goods like groceries and electronics. Analysts estimate these tariffs could add $1,250 to the annual cost of living for the average American household—a substantial burden for families already struggling with inflation. Additionally, according to the well-regarded Tax Foundation, the tariffs are projected to reduce GDP by 0.5% and result in the loss of approximately 292,000 jobs.

Keep ReadingShow less
Veterans diagnosed with asbestos-related diseases should apply for compensation

An individual applying for a program online.

Getty Images, Inti St Clair

Veterans diagnosed with asbestos-related diseases should apply for compensation

In 1922, the U.S. Navy identified asbestos as the most efficient material for shipbuilding insulation and equipment production due to its heat resistance and durability. The naturally occurring asbestos mineral was also the most abundant and cost-effective material on the market. During the difficult WWII years, asbestos became critical to the U.S. Military, especially for the U.S. Navy and the U.S. Air Force: shipping and shipbuilding were essential, and parts of the military aircraft and incendiary bombs also contained asbestos.

Even as demand exceeded supply, in 1942, a presidential order banned the use of asbestos for non-military purposes until 1945. The application of asbestos-based material by the Military continued to increase until the 1970s when its carcinogenic nature came to light, and the use of asbestos started to be regulated but not banned.

Keep ReadingShow less
S.E. Cupp: Where is the Democratic Party’s Ronald Reagan?

President Joe Biden and President-elect Donald Trump arrive for the inauguration ceremony in the U.S. Capitol rotunda in Washington, D.C., on Jan. 20, 2025.

Getty Images/TCA, Melina Mara/POOL/AFP

S.E. Cupp: Where is the Democratic Party’s Ronald Reagan?

With all the attention deservedly on President Trump and what he intends to do with his defiant return to the White House, there’s a more than good chance we’ll spend the next four years consumed once again by all things Trump.

There’s already been a dizzying amount: a giant raft of executive orders; attacks on a constitutional amendment; his threats to invade sovereign nations; a seeming Nazi salute from one of his biggest surrogates; his sweeping Jan. 6 pardons; his beef with a bishop; his TikTok flip-flop; his billion-dollar meme coin controversy; scathing new allegations against one of his Cabinet picks; unilaterally renaming a body of water; a federal crackdown on DEI; promises of immigration raids across major cities. All this in just the first three days of Trump’s second term.

Keep ReadingShow less